View in EDS HTML Full Text PDF Full Text

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

Saved in:
Bibliographic Details
Title: First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Authors: He AR; Department of Medicine, Georgetown University Medical Center, Washington, DC, USA arh29@georgetown.edu., Cohen RB; Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA., Denlinger CS; Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA., Sama A; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Birnbaum A; Division of Hematology/Oncology, Rhode Island Hospital, Providence, Rhode Island, USA., Hwang J; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA., Sato T; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Lewis N; Translational Clinical Oncology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Mynderse M; Syneos Health, Raleigh, North Carolina, USA., Niland M; Eli Lilly and Company, Indianapolis, Indiana, USA., Giles J; Eli Lilly and Company, Indianapolis, Indiana, USA., Wallin J; Eli Lilly and Company, Stockholm, Sweden., Moser B; Eli Lilly and Company, Indianapolis, Indiana, USA., Zhang W; Eli Lilly and Company, Indianapolis, Indiana, USA., Walgren R; Eli Lilly and Company, Indianapolis, Indiana, USA., Plimack ER; Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA.
Source: The oncologist [Oncologist] 2019 Sep; Vol. 24 (9), pp. e930-e942. Date of Electronic Publication: 2019 Mar 04.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30833489
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22He+AR%22">He AR</searchLink>; Department of Medicine, Georgetown University Medical Center, Washington, DC, USA arh29@georgetown.edu.<br /><searchLink fieldCode="AU" term="%22Cohen+RB%22">Cohen RB</searchLink>; Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Denlinger+CS%22">Denlinger CS</searchLink>; Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Sama+A%22">Sama A</searchLink>; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Birnbaum+A%22">Birnbaum A</searchLink>; Division of Hematology/Oncology, Rhode Island Hospital, Providence, Rhode Island, USA.<br /><searchLink fieldCode="AU" term="%22Hwang+J%22">Hwang J</searchLink>; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Sato+T%22">Sato T</searchLink>; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Lewis+N%22">Lewis N</searchLink>; Translational Clinical Oncology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Mynderse+M%22">Mynderse M</searchLink>; Syneos Health, Raleigh, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Niland+M%22">Niland M</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Giles+J%22">Giles J</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Wallin+J%22">Wallin J</searchLink>; Eli Lilly and Company, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Moser+B%22">Moser B</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Walgren+R%22">Walgren R</searchLink>; Eli Lilly and Company, Indianapolis, Indiana, USA.<br /><searchLink fieldCode="AU" term="%22Plimack+ER%22">Plimack ER</searchLink>; Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2019 Sep; Vol. 24 (9), pp. e930-e942. <i>Date of Electronic Publication: </i>2019 Mar 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30833489
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1634/theoncologist.2018-0411
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e930
    Titles:
      – TitleFull: First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: He AR
      – PersonEntity:
          Name:
            NameFull: Cohen RB
      – PersonEntity:
          Name:
            NameFull: Denlinger CS
      – PersonEntity:
          Name:
            NameFull: Sama A
      – PersonEntity:
          Name:
            NameFull: Birnbaum A
      – PersonEntity:
          Name:
            NameFull: Hwang J
      – PersonEntity:
          Name:
            NameFull: Sato T
      – PersonEntity:
          Name:
            NameFull: Lewis N
      – PersonEntity:
          Name:
            NameFull: Mynderse M
      – PersonEntity:
          Name:
            NameFull: Niland M
      – PersonEntity:
          Name:
            NameFull: Giles J
      – PersonEntity:
          Name:
            NameFull: Wallin J
      – PersonEntity:
          Name:
            NameFull: Moser B
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Walgren R
      – PersonEntity:
          Name:
            NameFull: Plimack ER
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2019 Sep
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1